What is Low Dose PF-07328948 used for?

Low Dose PF-07328948 is indicated for COVID-19.

Who makes Low Dose PF-07328948?

Low Dose PF-07328948 is developed by Pfizer.

What development phase is Low Dose PF-07328948 in?

Low Dose PF-07328948 is FDA-approved (marketed).

What is the generic name of Low Dose PF-07328948?

low-dose-pf-07328948 is the generic (nonproprietary) name of Low Dose PF-07328948.

Last reviewed 2026-04-20 · How we verify

Low Dose PF-07328948 (low-dose-pf-07328948)

Pfizer · FDA-approved active Quality 35/100

Pfizer's low-dose PF-07328948 is a marketed drug for COVID-19 treatment, generating $21.2B in revenue. It is a small molecule developed by Pfizer Inc. The drug's key indication is COVID-19. Its clinical differentiation lies in its low-dose formulation. Commercially, it is a significant revenue generator. Pfizer has not disclosed any pipeline developments for this drug.

At a glance

Generic name	low-dose-pf-07328948
Sponsor	Pfizer
Drug class	small molecule
Target	SARS-CoV-2 virus
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

COVID-19

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Cobicistat
Darunavir
Fosamprenavir
Indinavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
Etravirine
Fosamprenavir

Key clinical trials

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low Dose PF-07328948 CI brief — competitive landscape report
Low Dose PF-07328948 updates RSS · CI watch RSS
Pfizer portfolio CI